Yoshitaka Isaka1, Takayuki Hamano2,3, Hideki Fujii4, Yoshihiro Tsujimoto5, Fumihiko Koiwa6, Yusuke Sakaguchi2, Ryoichi Tanaka7,8, Noriyuki Tomiyama9, Fuminari Tatsugami10, Satoshi Teramukai11. 1. Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan isaka@kid.med.osaka-u.ac.jp. 2. Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan. 3. Department of Nephrology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. 4. Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine. 5. Division of Internal Medicine, Medical Corporation Aijinkai Inoue Hospital, Suita, Japan. 6. Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan. 7. Department of Radiology, Iwate Medical University School of Medicine, Shiwa, Japan. 8. Division of Dental Radiology, Department of Reconstructive Oral and Maxillofacial Surgery, Iwate Medical University School of Dentistry, Shiwa, Japan. 9. Department of Radiology, Osaka University Graduate School of Medicine, Suita, Japan. 10. Department of Diagnostic Radiology, Hiroshima University, Hiroshima, Japan. 11. Department of Biostatistics, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Abstract
BACKGROUND: In patients on maintenance dialysis, cardiovascular mortality risk is remarkably high, which can be partly explained by severe coronary artery calcification (CAC). Hyperphosphatemia has been reported to be associated with the severity of CAC. However, the optimal phosphate range in patients on dialysis remains unknown. This study was planned to compare the effects on CAC progression of two types of noncalcium-based phosphate binders and of two different phosphate target ranges. METHODS: We conducted a randomized, open-label, multicenter, interventional trial with a two by two factorial design. A total of 160 adults on dialysis were enrolled and randomized to the sucroferric oxyhydroxide or lanthanum carbonate group, with the aim of reducing serum phosphate to two target levels (3.5-4.5 mg/dl in the strict group and 5.0-6.0 mg/dl in the standard group). The primary end point was percentage change in CAC scores during the 12-month treatment. RESULTS: The full analysis set included 115 patients. We observed no significant difference in percentage change in CAC scores between the lanthanum carbonate group and the sucroferric oxyhydroxide group. On the other hand, percentage change in CAC scores in the strict group (median of 8.52; interquartile range, -1.0-23.9) was significantly lower than that in the standard group (median of 21.8; interquartile range, 10.0-36.1; P=0.006). This effect was pronounced in older (aged 65-74 years) versus younger (aged 20-64 years) participants (P value for interaction =0.003). We observed a similar finding for the absolute change in CAC scores. CONCLUSIONS: Further study with a larger sample size is needed, but strict phosphate control shows promise for delaying progression of CAC in patients undergoing maintenance hemodialysis. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Evaluate the New Phosphate Iron-Based Binder Sucroferric Oxyhydroxide in Dialysis Patients with the Goal of Advancing the Practice of EBM (EPISODE), jRCTs051180048.
BACKGROUND: In patients on maintenance dialysis, cardiovascular mortality risk is remarkably high, which can be partly explained by severe coronary artery calcification (CAC). Hyperphosphatemia has been reported to be associated with the severity of CAC. However, the optimal phosphate range in patients on dialysis remains unknown. This study was planned to compare the effects on CAC progression of two types of noncalcium-based phosphate binders and of two different phosphate target ranges. METHODS: We conducted a randomized, open-label, multicenter, interventional trial with a two by two factorial design. A total of 160 adults on dialysis were enrolled and randomized to the sucroferric oxyhydroxide or lanthanum carbonate group, with the aim of reducing serum phosphate to two target levels (3.5-4.5 mg/dl in the strict group and 5.0-6.0 mg/dl in the standard group). The primary end point was percentage change in CAC scores during the 12-month treatment. RESULTS: The full analysis set included 115 patients. We observed no significant difference in percentage change in CAC scores between the lanthanum carbonate group and the sucroferric oxyhydroxide group. On the other hand, percentage change in CAC scores in the strict group (median of 8.52; interquartile range, -1.0-23.9) was significantly lower than that in the standard group (median of 21.8; interquartile range, 10.0-36.1; P=0.006). This effect was pronounced in older (aged 65-74 years) versus younger (aged 20-64 years) participants (P value for interaction =0.003). We observed a similar finding for the absolute change in CAC scores. CONCLUSIONS: Further study with a larger sample size is needed, but strict phosphate control shows promise for delaying progression of CAC in patients undergoing maintenance hemodialysis. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Evaluate the New Phosphate Iron-Based Binder Sucroferric Oxyhydroxide in Dialysis Patients with the Goal of Advancing the Practice of EBM (EPISODE), jRCTs051180048.
Authors: Jorge B Cannata-Andía; José L Fernández-Martín; Francesco Locatelli; Gérard London; José L Gorriz; Jürgen Floege; Markus Ketteler; Aníbal Ferreira; Adrian Covic; Boleslaw Rutkowski; Dimitrios Memmos; Willem-Jan Bos; Vladimir Teplan; Judit Nagy; Christian Tielemans; Dierik Verbeelen; David Goldsmith; Reinhard Kramar; Pierre-Yves Martin; Rudolf P Wüthrich; Drasko Pavlovic; Miha Benedik; José Emilio Sánchez; Pablo Martínez-Camblor; Manuel Naves-Díaz; Juan J Carrero; Carmine Zoccali Journal: Kidney Int Date: 2013-07-03 Impact factor: 10.612
Authors: Geert J Behets; Geert Dams; Stephen J Damment; Patrick Martin; Marc E De Broe; Patrick C D'Haese Journal: Am J Physiol Renal Physiol Date: 2013-11-06
Authors: Suresh Mathew; Kimberly S Tustison; Toshifumi Sugatani; Lala R Chaudhary; Leonard Rifas; Keith A Hruska Journal: J Am Soc Nephrol Date: 2008-04-16 Impact factor: 10.121
Authors: Francesca Tentori; Margaret J Blayney; Justin M Albert; Brenda W Gillespie; Peter G Kerr; Jürgen Bommer; Eric W Young; Tadao Akizawa; Takashi Akiba; Ronald L Pisoni; Bruce M Robinson; Friedrich K Port Journal: Am J Kidney Dis Date: 2008-06-02 Impact factor: 8.860
Authors: Jürgen Floege; Adrian C Covic; Markus Ketteler; Johannes F E Mann; Anjay Rastogi; Bruce Spinowitz; Edward M F Chong; Sylvain Gaillard; Laura J Lisk; Stuart M Sprague Journal: Nephrol Dial Transplant Date: 2015-02-16 Impact factor: 5.992
Authors: Olivier Phan; Marc Maillard; Hartmut H Malluche; Jean-Christophe Stehle; Felix Funk; Michel Burnier Journal: Biomed Res Int Date: 2015-06-29 Impact factor: 3.411
Authors: Connie M Rhee; Meijiao Zhou; Rachael Woznick; Claudy Mullon; Michael S Anger; Linda H Ficociello Journal: Int Urol Nephrol Date: 2022-08-11 Impact factor: 2.266